Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ole Lederballe Pedersen

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
Ugeskrift for Laeger|August 20, 2005
[Independent clinical intervention research--or evidence-biased medicine?]Ole Lederballe Pedersen
Ugeskrift for Laeger|November 17, 2004
[Dual blockade of the renin-angiotensin system--is it of clinical significance?]Ole Lederballe Pedersen
Ugeskrift for Laeger|March 21, 2006
[Home blood pressure measurement in general practice]Kent Lodberg Christensen, Ole Lederballe Pedersen
Ugeskrift for Laeger|February 26, 2003
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]Hans Ibsen, Lars H Lindholm, Ole Lederballe Pedersen, et al.
Ugeskrift for Laeger|February 26, 2003
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]Hans Ibsen, Ole Lederballe Pedersen, Björn Dahlöf, et al.
Ugeskrift for Laeger|June 16, 2009
[Pharmacological hypertension therapy]Ole Lederballe Pedersen, Kent Lodberg Christensen, Lia E Bang, et al.
Journal of Hypertension|February 7, 2007
Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudyOle Lederballe Pedersen, Giuseppe Mancia, Thomas Pickering, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
Current Medical Research and Opinion|February 10, 2007
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophyRichard B Devereux, Ulf de Faire, Frej Fyhrquist, et al.
Expert Opinion on Emerging Drugs|November 3, 2005
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockersSverre E Kjeldsen, Paulette A Lyle, Andrew M Tershakovec, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
Ugeskrift for Laeger|August 20, 2005
[Independent clinical intervention research--or evidence-biased medicine?]Ole Lederballe Pedersen
Ugeskrift for Laeger|November 17, 2004
[Dual blockade of the renin-angiotensin system--is it of clinical significance?]Ole Lederballe Pedersen
Ugeskrift for Laeger|March 21, 2006
[Home blood pressure measurement in general practice]Kent Lodberg Christensen, Ole Lederballe Pedersen
Ugeskrift for Laeger|February 26, 2003
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with diabetes mellitus in the LIFE-study]Hans Ibsen, Lars H Lindholm, Ole Lederballe Pedersen, et al.
Ugeskrift for Laeger|February 26, 2003
[The effect of losartan versus atenolol on cardiovascular morbidity and mortality in patients with hypertension and ECG-verified left ventricular hypertrophy in the LIFE-study]Hans Ibsen, Ole Lederballe Pedersen, Björn Dahlöf, et al.
Ugeskrift for Laeger|June 16, 2009
[Pharmacological hypertension therapy]Ole Lederballe Pedersen, Kent Lodberg Christensen, Lia E Bang, et al.
Journal of Hypertension|February 7, 2007
Ambulatory blood pressure monitoring after 1 year on valsartan or amlodipine-based treatment: a VALUE substudyOle Lederballe Pedersen, Giuseppe Mancia, Thomas Pickering, et al.
Lancet (London, England)|April 9, 2002
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenololBjörn Dahlöf, Richard B Devereux, Sverre E Kjeldsen, et al.
Current Medical Research and Opinion|February 10, 2007
Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophyRichard B Devereux, Ulf de Faire, Frej Fyhrquist, et al.
Expert Opinion on Emerging Drugs|November 3, 2005
Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockersSverre E Kjeldsen, Paulette A Lyle, Andrew M Tershakovec, et al.
Pageof 3